cccDNA Maintenance in Chronic Hepatitis B – Targeting the Matrix of Viral Replication

References

• who. Hepatitis B key facts. 2018.
   Google Scholar
• Dandri M, Petersen J. Mechanism of hepatitis B virus persistence in hepatocytes and its carcinogenic potential. Clin Infect Dis. 2016;Suppl 62(suppl 4):S281–S288. doi:10.1093/cid/ciw023
   Web of Science ®Google Scholar
• Cornberg M, Suk-Fong Lok A, Terrault NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference. J Hepatol. 2020;71(3):1070–1092.
   Web of Science ®Google Scholar
• Leistner CM, Gruen-Bernhard S, Glebe D. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol. 2008;10:122–133.18086046
   PubMed Web of Science ®Google Scholar
• Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife. 2012;3:e05570.
   Google Scholar
• Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972–1984. doi:10.1136/gutjnl-2015-30980926048673
   PubMed Web of Science ®Google Scholar
• Rabe B, Glebe D, Kann M. Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events. J Virol. 2006;80(11):5465–5473. doi:10.1128/JVI.02303-0516699026
   PubMed Web of Science ®Google Scholar
• Gallucci L, Kann M. Nuclear import of hepatitis B virus capsids and genome. Viruses. 2017;9(1):21. doi:10.3390/v9010021
   Web of Science ®Google Scholar
• Guo H, Xu C, Zhou T, et al. Characterization of the host factors required for hepadnavirus covalently closed circular (ccc) DNA formation. PLoS One. 2012;7(8):e43270. doi:10.1371/journal.pone.004327022912842
   PubMed Web of Science ®Google Scholar
• Schreiner S, Nassal M. A role for the host DNA damage response in hepatitis B virus cccDNA formation-and beyond? Viruses. 2017;9. doi:10.3390/v9050125
   Web of Science ®Google Scholar
• Guo H, Jiang D, Zhou T, et al. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol. 2007;81(22):12472–12484. doi:10.1128/JVI.01123-0717804499
   PubMed Web of Science ®Google Scholar
• Baumert TF, Verrier ER, Nassal M, et al. Host-targeting agents for treatment of hepatitis B virus infection. Curr Opin Virol. 2015;14:41–46. doi:10.1016/j.coviro.2015.07.00926262886
   PubMed Web of Science ®Google Scholar
• Qi Y, Gao Z, Xu G, et al. DNA polymerase κ is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus. PLoS Pathog. 2016;12(10):e1005893. doi:10.1371/journal.ppat.100589327783675
   PubMed Web of Science ®Google Scholar
• Koniger C, Wingert I, Marsmann M, et al. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A. 2014;111(40):E4244–E4253. doi:10.1073/pnas.140998611125201958
   PubMed Web of Science ®Google Scholar
• Bock C-T, Schranz P, Schroder CH, et al. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes. 1994;8(2):215–229. doi:10.1007/BF17030797975268
   PubMed Web of Science ®Google Scholar
• Bock CT, Schwinn S, Locarnini S, et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol. 2001;307(1):183–196. doi:10.1006/jmbi.2000.448111243813
   PubMed Web of Science ®Google Scholar
• Newbold JE, Xin H, Tencza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995;69(6):3350–3357. doi:10.1128/JVI.69.6.3350-3357.19957745682
   PubMed Web of Science ®Google Scholar
• Giersch K, Allweiss L, Volz T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2017;66(2):460–462. doi:10.1016/j.jhep.2016.09.02827826059
   PubMed Web of Science ®Google Scholar
• Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65(4):700–710. doi:10.1016/j.jhep.2016.05.02927245431
   PubMed Web of Science ®Google Scholar
• Liu Y, Jiang M, Xue J, et al. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol. 2019;19(1):53. doi:10.1186/s12876-019-0966-430991954
   PubMed Web of Science ®Google Scholar
• Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol. 2007;13:22–38. doi:10.3748/wjg.v13.i1.2217206752
   PubMed Web of Science ®Google Scholar
• Dembek C, Protzer U, Roggendorf M. Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. Curr Opin Virol. 2018;30:58–67. doi:10.1016/j.coviro.2018.04.00329751272
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Lewin SR. Immunopathogenesis: role of innate and adaptive immune responses. Semin Liver Dis. 2006;26(2):104–115. doi:10.1055/s-2006-93975516673289
   PubMed Web of Science ®Google Scholar
• Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol. 1994;68(3):2026–2030. doi:10.1128/JVI.68.3.2026-2030.19948107266
   PubMed Web of Science ®Google Scholar
• Lucifora J, Arzberger S, Durantel D, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol. 2011;55(5):996–1003. doi:10.1016/j.jhep.2011.02.01521376091
   PubMed Web of Science ®Google Scholar
• Riviere L, Gerossier L, Ducroux A, et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol. 2015;63(5):1093–1102. doi:10.1016/j.jhep.2015.06.02326143443
   PubMed Web of Science ®Google Scholar
• Tsuge M, Hiraga N, Akiyama R, et al. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. J Gen Virol. 2010;91(7):1854–1864. doi:10.1099/vir.0.019224-020219897
   PubMed Web of Science ®Google Scholar
• Levrero M, Pollicino T, Petersen J, et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009;51(3):581–592. doi:10.1016/j.jhep.2009.05.02219616338
   PubMed Web of Science ®Google Scholar
• Belloni L, Allweiss L, Guerrieri F, et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012;122(2):529–537. doi:10.1172/JCI5884722251702
   PubMed Web of Science ®Google Scholar
• Tropberger P, Mercier A, Robinson M, et al. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci U S A. 2015;112(42):E5715–E5724. doi:10.1073/pnas.151809011226438841
   PubMed Web of Science ®Google Scholar
• Quasdorff M, Protzer U. Control of hepatitis B virus at the level of transcription. J Viral Hepat. 2019;156(8):1392–1403.e7. doi:10.1111/j.1365-2893.2010.01315.x
   Web of Science ®Google Scholar
• Bar-Yishay I, Shaul Y, Shlomai A. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. Liver Int. 2011;31(3):282–290. doi:10.1111/j.1478-3231.2010.02423.x21281428
   PubMed Web of Science ®Google Scholar
• Mohd-Ismail NK, Lim Z, Gunaratne J, et al. Mapping the interactions of HBV cccDNA with host factors. Int J Mol Sci. 2019;20:4276.
   PubMed Web of Science ®Google Scholar
• Guo Y-H, Li Y-N, Zhao J-R, et al. HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state. Epigenetics. 2016;62(6):S281–S288. doi:10.4161/epi.6.6.15815
   Web of Science ®Google Scholar
• Chong CK, Cheng CYS, Tsoi SYJ, et al. Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. Antiviral Res. 2017;144:1–7. doi:10.1016/j.antiviral.2017.05.00328499864
   PubMed Web of Science ®Google Scholar
• Slagle BL, Bouchard MJ. Hepatitis B virus X and regulation of viral gene expression. Cold Spring Harb Perspect Med. 2010;91(3):a021402. doi:10.1101/cshperspect.a021402
   Web of Science ®Google Scholar
• Belloni L, Pollicino T, De Nicola F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A. 2009;106:19975–19979. doi:10.1073/pnas.090836510619906987
   PubMed Web of Science ®Google Scholar
• Decorsiere A, Mueller H, van Breugel PC, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature. 2016;531(7594):386–389. doi:10.1038/nature1717026983541
   PubMed Web of Science ®Google Scholar
• Sekiba K, Otsuka M, Ohno M, et al. Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction. Cell Mol Gastroenterol Hepatol. 2019;7:297–312. doi:10.1016/j.jcmgh.2018.10.01030704981
   PubMed Web of Science ®Google Scholar
• Mitra B, Guo H. Hepatitis B virus X protein crosses out Smc5/6 complex to maintain covalently closed circular DNA transcription. Hepatology. 2016;64(6):2246–2249. doi:10.1002/hep.2883427639252
   PubMedGoogle Scholar
• Abdul F, Filleton F, Gerossier L, et al. Smc5/6 antagonism by HBx is an evolutionarily conserved function of hepatitis B virus infection in mammals. J Virol. 2018;92(16). doi:10.1128/JVI.00769-18
   Web of Science ®Google Scholar
• Fu X, Song X, Li Y, et al. Hepatitis B virus X protein upregulates DNA methyltransferase 3A/3B and enhances SOCS-1CpG island methylation. Mol Med Rep. 2018;92(1):301–308. doi:10.3892/mmr.2015.4545
   Web of Science ®Google Scholar
• Andrisani OM. Deregulation of epigenetic mechanisms by the hepatitis B virus X protein in hepatocarcinogenesis. Viruses. 2013;5(3):858–872. doi:10.3390/v503085823507839
   PubMed Web of Science ®Google Scholar
• Vivekanandan P, Daniel HD-J, Kannangai R, et al. Hepatitis B virus replication induces methylation of both host and viral DNA. J Virol. 2010;84(9):4321–4329. doi:10.1128/JVI.02280-0920147412
   PubMed Web of Science ®Google Scholar
• Kim J-W, Lee SH, Park YS, et al. Replicative activity of hepatitis B virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis B virus infection. Intervirology. 2011;54(6):316–325. doi:10.1159/00032145021242658
   PubMed Web of Science ®Google Scholar
• Zhang X, Hou J, Lu M. Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs. Front Genet. 2013;4:202. doi:10.3389/fgene.2013.0020224133502
   PubMedGoogle Scholar
• Zhang Y, Mao R, Yan R, et al. Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection. PLoS One. 2014;9(10):e110442. doi:10.1371/journal.pone.011044225337821
   PubMed Web of Science ®Google Scholar
• Jain S, Chang -T-T, Chen S, et al. Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. Sci Rep. 2013;5(1):10478. doi:10.1038/srep10478
   Web of Science ®Google Scholar
• Hong X, Kim ES, Guo H. Epigenetic regulation of hepatitis B virus covalently closed circular DNA: implications for epigenetic therapy against chronic hepatitis B. Hepatology. 2017;66(6):2066–2077. doi:10.1002/hep.2947928833361
   PubMed Web of Science ®Google Scholar
• Dandri M. Epigenetic modulation in chronic hepatitis B virus infection. Semin Immunopathol. 2020;42(2):173–185. doi:10.1007/s00281-020-00780-632185454
   PubMed Web of Science ®Google Scholar
• Pollicino T, Belloni L, Raffa G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology. 2006;130(3):823–837. doi:10.1053/j.gastro.2006.01.00116530522
   PubMed Web of Science ®Google Scholar
• Cougot D, Allemand E, Riviere L, et al. Inhibition of PP1 phosphatase activity by HBx: a mechanism for the activation of hepatitis B virus transcription. Sci Signal. 2006;130(205):ra1. doi:10.1126/scisignal.2001906
   Web of Science ®Google Scholar
• Yang G, Feng J, Liu Y, et al. HAT1 signaling confers to assembly and epigenetic regulation of HBV cccDNA minichromosome. Theranostics. 2019;9(24):7345–7358. doi:10.7150/thno.3717331695772
   PubMed Web of Science ®Google Scholar
• Flecken T, Meier M-A, Skewes-Cox P, et al. Mapping the heterogeneity of histone modifications on hepatitis B virus DNA using liver needle biopsies obtained from chronically infected patients. J Virol. 2019;93(9). doi:10.1128/JVI.02036-18
   Web of Science ®Google Scholar
• Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell. 1986;47(3):451–460. doi:10.1016/0092-8674(86)90602-13768961
   PubMed Web of Science ®Google Scholar
• Wu -T-T, Coates L, Aldrics CE, et al. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology. 1990;175(1):255–261. doi:10.1016/0042-6822(90)90206-72155510
   PubMed Web of Science ®Google Scholar
• Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA – the holy grail to hepatitis B cure. J Hepatol. 2016;64(1):S41–S48. doi:10.1016/j.jhep.2016.02.00927084036
   PubMed Web of Science ®Google Scholar
• Ko C, Chakraborty A, Chou WM, et al. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. J Hepatol. 2018;69:1231–1241. doi:10.1016/j.jhep.2018.08.01230142426
   PubMed Web of Science ®Google Scholar
• Balagopal A, Hwang HS, Grudda T, et al. Single hepatocyte hepatitis B virus transcriptional landscape in HIV co-infection. J Infect Dis. 2020;221(9):1462–1469.31740931
   PubMed Web of Science ®Google Scholar
• Huang J-T, Yang Y, Hu Y-M, et al. A highly sensitive and robust method for hepatitis B virus covalently closed circular DNA detection in single cells and serum. J Mol Diagn. 2018;20(3):334–343. doi:10.1016/j.jmoldx.2018.01.01029656833
   PubMed Web of Science ®Google Scholar
• Volz T, Allweiss L, ḾBarek MB, et al. The entry inhibitor myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58(5):861–867. doi:10.1016/j.jhep.2012.12.00823246506
   PubMed Web of Science ®Google Scholar
• Laras A, Koskinas J, Dimou E, et al. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology. 2006;44(3):694–702. doi:10.1002/hep.2129916941694
   PubMed Web of Science ®Google Scholar
• Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology. 2007;133(3):843–852. doi:10.1053/j.gastro.2007.06.05717854594
   PubMed Web of Science ®Google Scholar
• Werle–Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1. Gastroenterology. 2004;126(7):1750–1758. doi:10.1053/j.gastro.2004.03.01815188170
   PubMed Web of Science ®Google Scholar
• Allweiss L, Volz T, Lutgehetmann M, et al. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J Hepatol. 2014;60(3):500–507. doi:10.1016/j.jhep.2013.10.02124398036
   PubMed Web of Science ®Google Scholar
• Allweiss L, Volz T, Giersch K, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut. 2018;67(3):542–552. doi:10.1136/gutjnl-2016-31216228428345
   PubMed Web of Science ®Google Scholar
• Kock J, Rosler C, Zhang -J-J, et al. Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog. 2015;64(9):e1001082. doi:10.1371/journal.ppat.1001082
   Web of Science ®Google Scholar
• Dandri M, Burda MR, Will H, et al. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovirIn vitro do not lead to reduction of the closed circular DNA. Hepatology. 2000;32(1):139–146. doi:10.1053/jhep.2000.870110869302
   PubMed Web of Science ®Google Scholar
• Moraleda G, Saputelli J, Aldrich CE, et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol. 1997;71:9392–9399.9371599
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yamamoto T, Cullen J, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol. 2001;75(1):311–322. doi:10.1128/JVI.75.1.311-322.200111119601
   PubMed Web of Science ®Google Scholar
• Addison WR, Walters K-A, Wong WWS, et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol. 2002;76(12):6356–6363. doi:10.1128/JVI.76.12.6356-6363.200212021368
   PubMed Web of Science ®Google Scholar
• Lai C-L, Wong D, Ip P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66(2):275–281. doi:10.1016/j.jhep.2016.08.02227639844
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–684. doi:10.1002/hep.2128216941693
   PubMed Web of Science ®Google Scholar
• Lutgehetmann M, Volzt T, Quaas A, et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther. 2008;13:57–66.18389899
   PubMed Web of Science ®Google Scholar
• Bowden S, Locarnini S, Chang T-T, et al. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol. 2006;80(15):5465–5473. doi:10.3748/wjg.v21.i15.4644
   Web of Science ®Google Scholar
• Boyd A, Lacombe K, Lavocat F, et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol. 2015;21(4):4644–4651. doi:10.1016/j.jhep.2016.05.014
   Web of Science ®Google Scholar
• Huang Q, Zhou B, Cai D, et al. Rapid turnover of HBV cccDNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients. Hepatology. 2020. doi:10.1002/hep.31240
   Web of Science ®Google Scholar
• Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients‘ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response. Nat Med. 1996;2(10):1104–1108. doi:10.1038/nm1096-11048837608
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012;61(12):1754–1764. doi:10.1136/gutjnl-2011-30107322157327
   PubMed Web of Science ®Google Scholar
• Dandri M, Petersen J. Hepatitis B virus cccDNA clearance: killing for curing? Hepatology. 2005;42(6):1453–1455. doi:10.1002/hep.2097616317676
   PubMedGoogle Scholar
• Reaiche-Miller GY, Thorpe M, Low HC, et al. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver. Virology. 2013;446(1–2):357–364. doi:10.1016/j.virol.2013.08.01424074600
   PubMed Web of Science ®Google Scholar
• Mason WS, Gill US, Litwin S, et al. HBV DNA Integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology. 2016;151(5):986–998.e4. doi:10.1053/j.gastro.2016.07.01227453547
   PubMed Web of Science ®Google Scholar
• Mason WS, Low H-C, Xu C, et al. Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection. J Virol. 2009;83(17):8396–8408. doi:10.1128/JVI.00700-0919535448
   PubMed Web of Science ®Google Scholar
• Li M, Sohn JA, Seeger C. Distribution of hepatitis B virus nuclear DNA. J Virol. 2018;92.
   Web of Science ®Google Scholar
• Chen F, Zhang J, Wen B, et al. HBV/HCV dual infection impacts viral load, antibody response, and cytokine expression differently from HBV or HCV single infection. Sci Rep. 2016;6(1):39409. doi:10.1038/srep3940928009018
   PubMed Web of Science ®Google Scholar
• Lechardeur D, Sohn K-J, Haardt M, et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Therapy. 1999;6(4):482–497. doi:10.1038/sj.gt.330086710476208
   PubMed Web of Science ®Google Scholar
• Quetier I, Brezillon N, Duriez M, et al. Hepatitis B virus HBx protein impairs liver regeneration through enhanced expression of IL-6 in transgenic mice. J Hepatol. 2013;59(2):285–291. doi:10.1016/j.jhep.2013.03.02123542345
   PubMed Web of Science ®Google Scholar
• Kah J, Koh S, Volz T, et al. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. J Clin Invest. 2017;127(8):3177–3188. doi:10.1172/JCI9302428737510
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Le Bert N. Immunotherapy for chronic hepatitis B virus infection. Gut Liver. 2018;12(5):497–507. doi:10.5009/gnl1723329316747
   PubMed Web of Science ®Google Scholar
• Wisskirchen K, Kah J, Malo A, et al. T cell receptor grafting allows virological control of hepatitis B virus infection. J Clin Invest. 2019;129(7):2932–2945. doi:10.1172/JCI12022831039136
   PubMed Web of Science ®Google Scholar
• Hadziyannis E, Sialevris K, Georgiou A, et al. Analysis of serum alpha-fetoprotein-L3% and des-gamma carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total alpha-fetoprotein levels. Oncol Rep. 2013;29:835–839. doi:10.3892/or.2012.214723174906
   PubMed Web of Science ®Google Scholar
• Honer Zu Siederdissen C, Rinker F, Maasoumy B, et al. Viral and host responses after stopping long-term Nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Infect Dis. 2016;214(10):1492–1497. doi:10.1093/infdis/jiw41227609808
   PubMed Web of Science ®Google Scholar
• Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005;128:1890–1897. doi:10.1053/j.gastro.2005.03.00915940624
   PubMed Web of Science ®Google Scholar
• Wong DK, Yuen MF, Ngai VW, et al. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther. 2006;11:909–916.17302253
   PubMed Web of Science ®Google Scholar
• Zheng Q, Zhu YY, Chen J, et al. Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss. J Viral Hepat. 2014;21:909–916. doi:10.1111/jvh.1226124888640
   PubMed Web of Science ®Google Scholar
• Tavis JE, Zoidis G, Meyers MJ, et al. Chemical approaches to inhibiting the hepatitis B virus ribonuclease H. ACS Infect Dis. 2005;128(5):1890–1898. doi:10.1021/acsinfecdis.8b00045
   Web of Science ®Google Scholar
• Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol. 2019;5(3):655–658. doi:10.1038/nbt1389
   Web of Science ®Google Scholar
• Lutgehetmann M, Mancke LV, Volz T, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55(3):685–694. doi:10.1002/hep.2475822031488
   PubMed Web of Science ®Google Scholar
• Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490–498. doi:10.1016/j.jhep.2016.04.01627132170
   PubMed Web of Science ®Google Scholar
• Zhang TY, Yuan Q, Zhao JH, et al. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut. 2016;65:658–671. doi:10.1136/gutjnl-2014-30896426423112
   PubMed Web of Science ®Google Scholar
• Brezillon N, Brunelle MN, Massinet H, et al. Antiviral activity of bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS One. 2011;6:e25096. doi:10.1371/journal.pone.002509622162746
   PubMed Web of Science ®Google Scholar
• Klumpp K, Shimada T, Allweiss L, et al. Efficacy of NVR 3–778, alone and in combination with pegylated interferon, vs entecavir in uPA/SCID mice with humanized livers and HBV infection. Gastroenterology. 2018;154:652–62 e8. doi:10.1053/j.gastro.2017.10.01729079518
   PubMed Web of Science ®Google Scholar
• Wang XY, Wei ZM, Wu GY, et al. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir Ther. 2012;17:793–803. doi:10.3851/IMP215222668794
   PubMed Web of Science ®Google Scholar
• Yuen MF, Gane EJ, Kim DJ, et al. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3–778 in patients with chronic HBV infection. Gastroenterology. 2019;156:1392–403 e7. doi:10.1053/j.gastro.2018.12.02330625297
   PubMed Web of Science ®Google Scholar
• Xu YB, Yang L, Wang GF, et al. Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion. Antiviral Res. 2014;107:6–15. doi:10.1016/j.antiviral.2014.04.00224746457
   PubMed Web of Science ®Google Scholar
• Bazinet M, Pantea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection naive to Nucleos(t)ide therapy. Gastroenterology. 2020;158:2180–2194. doi:10.1053/j.gastro.2020.02.05832147484
   PubMed Web of Science ®Google Scholar
• Mueller H, Wildum S, Luangsay S, et al. A novel orally available small molecule that inhibits hepatitis B virus expression. J Hepatol. 2018;68:412–420. doi:10.1016/j.jhep.2017.10.01429079285
   PubMed Web of Science ®Google Scholar
• Thi EP, Dhillon AP, Ardzinski A, et al. ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection. ACS Infect Dis. 2019;5:725–737. doi:10.1021/acsinfecdis.8b0019130403127
   PubMed Web of Science ®Google Scholar
• Kornyeyev D, Ramakrishnan D, Voitenleitner C, et al. Spatiotemporal analysis of hepatitis B virus X protein in primary human hepatocytes. J Virol. 2019;93. doi:10.1128/JVI.00248-19
   Web of Science ®Google Scholar
• Lin SR, Yang HC, Kuo YT, et al. The CRISPR/cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids. 2014;3:e186. doi:10.1038/mtna.2014.3825137139
   PubMedGoogle Scholar
• Kostyushev D, Brezgin S, Kostyusheva A, et al. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus. Cell Mol Life Sci. 2019;76(9):1779–1794. doi:10.1007/s00018-019-03021-830673820
   PubMed Web of Science ®Google Scholar
• Seeger C, Sohn JA. Targeting hepatitis B virus with CRISPR/cas9. Mol Ther Nucleic Acids. 2014;3:e216. doi:10.1038/mtna.2014.6825514649
   PubMedGoogle Scholar
• Kennedy EM, Kornepati AV, Cullen BR. Targeting hepatitis B virus cccDNA using CRISPR/cas9. Antiviral Res. 2015;123:188–192. doi:10.1016/j.antiviral.2015.10.00426476375
   PubMed Web of Science ®Google Scholar
• Yang YC, Chen YH, Kao JH, et al. Permanent Inactivation of HBV genomes by CRISPR/cas9-mediated non-cleavage base editing. Mol Ther Nucleic Acids. 2020;20:480–490. doi:10.1016/j.omtn.2020.03.00532278307
   PubMedGoogle Scholar
• Yu H-B, Jiang H, Cheng S-T, et al. AGK2, A SIRT2 inhibitor, inhibits hepatitis B virus replication in vitro and in vivo. Int J Med Sci. 2018;15(12):1356–1364. doi:10.7150/ijms.2612530275764
   PubMed Web of Science ®Google Scholar
• Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18:827–844.31455905
   PubMed Web of Science ®Google Scholar
• Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343(6176):1221–1228. doi:10.1126/science.124346224557838
   PubMed Web of Science ®Google Scholar
• Wieland SF, Spangenberg HC, Thimme R, et al. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci USA. 2004;101(7):2129–2134. doi:10.1073/pnas.030847810014764900
   PubMed Web of Science ®Google Scholar
• Murray JM, Wieland SF, Purcell RH, et al. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci U S A. 2005;102(49):17780–17785. doi:10.1073/pnas.050891310216306261
   PubMed Web of Science ®Google Scholar
• Xia Y, Stadler D, Lucifora J, et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016;150(1):194–205. doi:10.1053/j.gastro.2015.09.02626416327
   PubMed Web of Science ®Google Scholar
• Asabe S, Wieland SF, Chattopadhyay PK, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol. 2009;83(19):9652–9662. doi:10.1128/JVI.00867-0919625407
   PubMed Web of Science ®Google Scholar
• Wieland SF, Eustaquio A, Whitten-Bauer C, et al. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A. 2005;102(28):9913–9917. doi:10.1073/pnas.050427310215994231
   PubMed Web of Science ®Google Scholar
• Uprichard SL, Wieland SF, Althage A, et al. Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A. 2003;100(3):1310–1315. doi:10.1073/pnas.25277359912552098
   PubMed Web of Science ®Google Scholar
• Allweiss L, Giersch K, Volz T, et al. PS-155-HBV entry inhibition after interferon alpha treatment hinders HBV rebound in hepatocytes that became negative for all HBV markers during interferon treatment. J Hepatol. 2019;70(1):e98. doi:10.1016/S0618-8278(19)30173-2
   Web of Science ®Google Scholar
• Vigano M, Grossi G, Loglio A, et al. Treatment of hepatitis B: is there still a role for interferon? Liver Int. 2018;38(Suppl 1):79–83. doi:10.1111/liv.1363529427498
   PubMed Web of Science ®Google Scholar